{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Frio-bravo-qweek.simplecast.com%2Fepisodes%2Fepisode-142-tirzepatide-ii-gZNxfKEx","width":444,"version":"1.0","type":"rich","title":"Episode 142: Tirzepatide II","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/e7f25359-702b-47e8-97f2-d7f32a376648/89b65036-b2fa-4527-9fd4-f80317fd5fc8/rio_bravo_qweek_podcastlogonew.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/c74d43de-7e8d-42f5-848e-00b71537b5b2\" height=\"200\" width=\"100%\" title=\"Episode 142: Tirzepatide II\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Episode 142: Tirzepatide II\nFuture Dr. Beuca explains that tirzepatide has shown benefits in patients with obesity that go beyond its weight-reducing effects and includes reduction of blood pressure, among others. Dr. Arreaza explains that Wegovy (semaglutide approved for weight loss) is also very beneficial for weight loss and explains. \nWritten by Maria Beuca, MSIV, Ross University School of Medicine. Comments by Hector Arreaza, MD.\n"}